• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

    1.170 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,081
    Open 1.170
    Bid (Size) 1.200 (20,100)
    Ask (Size) 1.210 (300)
    Prev. Close 1.170
    Today's Range 1.170 - 1.170
    52wk Range 0.3258 - 1.510
    Shares Outstanding 46,166,980
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Top movers in Tuesday's after hours session ↗
    Via Chartmill
    News headline image
    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
    Issued on behalf of Oncolytics Biotech Inc. 
    From USA News Group
    Via GlobeNewswire

    Performance

    YTD
    +18.9%
    +18.9%
    1 Month
    +20.8%
    +20.8%
    3 Month
    -0.8%
    -0.8%
    6 Month
    -1.7%
    -1.7%
    1 Year
    +40.0%
    +40.0%

    More News

    Read More
    News headline image
    THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
    From USA News Group
    Via GlobeNewswire
    News headline image
    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
    From Equity Insider
    Via GlobeNewswire
    News headline image
    The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    THE CHOKE POINT: 5 Assets That Control the Bottleneck
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
    From USA News Group
    Via GlobeNewswire
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
    From USA News Group
    Via GlobeNewswire
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    Via Chartmill
    News headline image
    UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
    From USA News Group
    Via GlobeNewswire
    News headline image
    The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
    From USA News Group
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
    From Oncolytics Biotech Inc.
    Via Business Wire
    News headline image
    Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
    From Oncolytics Biotech® Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 8, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Oncolytics Biotech Inc. - Common Shares publicly traded?
    Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
    What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
    Oncolytics Biotech Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
    The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONCY on the Nasdaq Stock Market
    What is the current price of Oncolytics Biotech Inc. - Common Shares?
    The current price of Oncolytics Biotech Inc. - Common Shares is 1.170
    When was Oncolytics Biotech Inc. - Common Shares last traded?
    The last trade of Oncolytics Biotech Inc. - Common Shares was at 01/21/26 04:00 PM ET
    What is the market capitalization of Oncolytics Biotech Inc. - Common Shares?
    The market capitalization of Oncolytics Biotech Inc. - Common Shares is 54.02M
    How many shares of Oncolytics Biotech Inc. - Common Shares are outstanding?
    Oncolytics Biotech Inc. - Common Shares has 54M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.